Joe Hogan is a respected business leader in medical technology and precision engineering. He is a successful managing director and brings extensive experience from various industries such as healthcare, technology and industrial automation to the supervisory board of the avatera group.

In addition to his role at avatera, Mr Hogan serves as president and CEO of Align Technology, a leading global medical technology company with annual sales of approximately $2.2 billion. Prior to joining Align, Joe was CEO of ABB, a global power and automation technology company based in Zurich, Switzerland. He also spent 25 years with General Electric ("GE") in a variety of leadership and management positions, including eight years as CEO of GE Healthcare.

Ian Read is the former Chairman and CEO of the biopharmaceutical company Pfizer. Mr Read created more than $240 billion of shareholder value. He stands for good governance, growth and value creation and the ability to transform companies to become strong and successful market leaders.

Mr Read is presently Chairman of DXC, a board member of Kimberly-Clark Corporation and he serves as an Operating Executive in the Global Healthcare Group for the Carlyle Group. Mr Read will join the board of directors of new company Viatris upon the completion of the merger between Mylan and Upjohn.

Ian Read joined Pfizer in 1978 as an operational auditor. From then until 2010 he worked in various leadership roles with increasing responsibility and successfully developed Pfizer’s Worldwide Biopharmaceutical Businesses. In 2010, he became CEO and in 2011, Chairman of Pfizer and retired from these positions in 2018 and 2019, respectively.

Dr. William (Jay) Gerald Austen Jr. is a professor of surgery at Harvard Medical School and also serves as chief physician to the plastic, reconstructive, and burns surgery departments of Massachusetts General Hospital. Owing to his clinical experience, he is an authority on medical device innovation and has been instrumental in the development of numerous patents and prototypes for anti-ageing, rejuvenation and scar therapy.

Dr. Austen has published extensively in the field of plastic surgery with more than 100 publications reviewed by experts and has filed or granted more than 100 patents in the USA and internationally.

Oliver Kupka has served as CEO of avateramedical GmbH since December 2019. Before, he was already appointed as a member of the management board of the avateramedical N.V.

Mr. Kupka has extensive management experience in the field of medical technology. From 2012 to 2018 he was a Managing Director of the World of Medicine Group in Berlin and also served as Senior Vice President Minimal Invasive Surgery for Novanta Inc. in 2018. Before that Mr. Kupka held various leading positions within BBraun AG, including as a long-standing member of the Executive Board of the branch in Brazil and as a Supervisory Board member of various country organizations in Latin America and the regional Management Board Latin America of the Aesculap division.

Mr. Kupka has a degree in International Business Administration and a MBA from the University of St. Thomas, USA.

Dr Dr Peter Wiesing served as CEO of the avateramedical GmbH from June 2017 until December 2019. In November 2019 he was appointed as member of the management board of avateramedical N.V.

Currently, Mr Wiesing is serving in various boards. Over the past 15 years he held various management and executive positions in the medical technology, finance and IT sectors.

Dr Dr Wiesing holds a master's degree in physics, a PhD in economics and a further PhD in neuroscience. He was also a research associate at the Salk Institute, La Jolla and MIT, Cambridge MA.